Literature DB >> 29895894

NMDAR-independent, cAMP-dependent antidepressant actions of ketamine.

Nathan H Wray1, Jeffrey M Schappi2, Harinder Singh2, Nicolas B Senese2,3, Mark M Rasenick4,5,6,7.   

Abstract

Ketamine produces rapid and robust antidepressant effects in depressed patients within hours of administration, often when traditional antidepressant compounds have failed to alleviate symptoms. We hypothesized that ketamine would translocate Gαs from lipid rafts to non-raft microdomains, similarly to other antidepressants but with a distinct, abbreviated treatment duration. C6 glioma cells were treated with 10 µM ketamine for 15 min, which translocated Gαs from lipid raft domains to non-raft domains. Other NMDA antagonist did not translocate Gαs from lipid raft to non-raft domains. The ketamine-induced Gαs plasma membrane redistribution allows increased functional coupling of Gαs and adenylyl cyclase to increase intracellular cyclic adenosine monophosphate (cAMP). Moreover, increased intracellular cAMP increased phosphorylation of cAMP response element-binding protein (CREB), which, in turn, increased BDNF expression. The ketamine-induced increase in intracellular cAMP persisted after knocking out the NMDA receptor indicating an NMDA receptor-independent effect. Furthermore, 10 µM of the ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) also induced Gαs redistribution and increased cAMP. These results reveal a novel antidepressant mechanism mediated by acute ketamine treatment that may contribute to ketamine's powerful antidepressant effect. They also suggest that the translocation of Gαs from lipid rafts is a reliable hallmark of antidepressant action that might be exploited for diagnosis or drug development.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29895894      PMCID: PMC8011999          DOI: 10.1038/s41380-018-0083-8

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  31 in total

Review 1.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 2.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

3.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

Review 4.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Annu Rev Med       Date:  2014-10-17       Impact factor: 13.739

Review 5.  Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

Authors:  D Jeffrey Newport; Linda L Carpenter; William M McDonald; James B Potash; Mauricio Tohen; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2015-10       Impact factor: 18.112

6.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

Review 7.  The epidemiology of depression across cultures.

Authors:  Ronald C Kessler; Evelyn J Bromet
Journal:  Annu Rev Public Health       Date:  2013       Impact factor: 21.981

8.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

9.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962

10.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.

Authors:  C Yang; Y Shirayama; J-c Zhang; Q Ren; W Yao; M Ma; C Dong; K Hashimoto
Journal:  Transl Psychiatry       Date:  2015-09-01       Impact factor: 6.222

View more
  41 in total

1.  Ketamine Increases Proliferation of Human iPSC-Derived Neuronal Progenitor Cells via Insulin-Like Growth Factor 2 and Independent of the NMDA Receptor.

Authors:  Alessandra Grossert; Narges Zare Mehrjardi; Sarah J Bailey; Mark A Lindsay; Jürgen Hescheler; Tomo Šarić; Nicole Teusch
Journal:  Cells       Date:  2019-09-24       Impact factor: 6.600

Review 2.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 3.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 4.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 5.  Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Authors:  Andrew J Polis; Paul J Fitzgerald; Pho J Hale; Brendon O Watson
Journal:  Behav Brain Res       Date:  2019-08-13       Impact factor: 3.332

6.  Homeostatic cAMP regulation by the RGS7 complex controls depression-related behaviors.

Authors:  Cesare Orlandi; Laurie P Sutton; Brian S Muntean; Chenghui Song; Kirill A Martemyanov
Journal:  Neuropsychopharmacology       Date:  2018-10-11       Impact factor: 7.853

7.  (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.

Authors:  Lace M Riggs; Yasco Aracava; Panos Zanos; Jonathan Fischell; Edson X Albuquerque; Edna F R Pereira; Scott M Thompson; Todd D Gould
Journal:  Neuropsychopharmacology       Date:  2019-06-19       Impact factor: 7.853

8.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.

Authors:  Jaclyn N Highland; Patrick J Morris; Panos Zanos; Jacqueline Lovett; Soumita Ghosh; Amy Q Wang; Carlos A Zarate; Craig J Thomas; Ruin Moaddel; Todd D Gould
Journal:  J Psychopharmacol       Date:  2018-11-29       Impact factor: 4.153

Review 9.  Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine's Antisuicidal Actions.

Authors:  Aiste Lengvenyte; Emilie Olié; Philippe Courtet
Journal:  Curr Psychiatry Rep       Date:  2019-12-03       Impact factor: 5.285

Review 10.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.